Imeglimin Hydrochloride: A Novel Approach to Type 2 Diabetes Management
Main Article Content
Abstract
Imeglimin hydrochloride is an novel drug evolve for the treatment of type 2 diabetes mellitus. It is characterized by its unique mechanism of action, targeting both pancreatic beta cells and peripheral tissues to improve insulin secretion and sensitivity. Early clinical trials showed promise in reducing blood sugar levels, but further research was needed to determine its safety and effectiveness. Some reported side effects included gastrointestinal symptoms like nausea and diarrhea. The regulatory status of Imeglimin varied by region, and patients were advised to consult with healthcare professionals for the latest information on its availability and use. Validation of imeglimin hydrochloride and its enantiomers, drug release patterns of the nanofibers, comparing its impact with other available drug like metformin, method of action by targeting mitrocondria, pharmacokinetics and therapeutic effect of imeglimin hydrochloride, Imeglimin treatment, both short- and long-term, counteracts the metabolic syndrome's cardiorenal dysfunction, its Potential Ketoacidosis, its solubility and UV-Spectrophotometry. [1]
Downloads
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
Hallakou-Bozec S, Vial G, Kergoat M, Fouqueray P, Bolze S, Borel AL, Fontaine E, Moller DE. Mechanism of action of Imeglimin: A novel therapeutic agent for type 2 diabetes. Diabetes Obes Metab. 2021 Mar;23(3):664-673. doi: 10.1111/dom.14277. Epub 2020 Dec 29. PMID: 33269554; PMCID: PMC8049051.
Fleifel M, Fleifel B, El Alam A. Diabetes Mellitus across the Arabo-Islamic World: A Revolution. Int J Endocrinol. 2023 Nov 10;2023:5541808. doi: 10.1155/2023/5541808. PMID: 38021083; PMCID: PMC10656201.
Ramalingam S, Subramania M N, Basuvan B, Jaganathan R, Dhavamani A J, Kandukuri N K, Parimi R V, Bodduna S; A sensitive direct chiral liquid chromatography tandem mass spectrometry method for the enantio Selective analysis of imeglimin in formulation. Journal of Applied Pharmaceutical Science , 2023, Vol. 13(07) , 214-219
Alamer A A, Alsaleh N B, Aodah A H, Alshehri A A, Almughem F A, Alqahtani S H, Alfassam H A, Tawfik E A; Development of Imeglimin Electrospun Nanofibers as a Potential Buccal Antidiabetic Therapeutic Approach. Pharmaceutics ,2023 Vol.15 (1208).
Hozumi K, Sugawara K, Ishihara K, Ishihara N, Ogawa W; Effects of imeglimin on mitochondrial function, AMPK activity, and gene expression in hepatocytes Journal of Scientific Reports, 2023, Vol. 13(746).
Clemence C, Fouqueray P, Sébastien B; In Vitro Investigation, Pharmacokinetics, and Disposition of Imeglimin, a Novel Oral Antidiabetic Drug, in Preclinical Species and Humans. Journal of drug metabolism and deposition, 2020, Vol. (48), 1330–1346.
Rautela A, Papola R, Ashok P K, Bora K S; A Review on Imeglimin Hydrochloride Immediate Release Tablet. International journal of pharmacy and pharmaceutical reaserach, 2023, Vol. 27, (286-297).
Crabtree T S, Defronzo R A, Ryder R E, Bailey C J; Imeglimin, a novel, first in-class, blood glucose-lowering agent: a systematic review and meta-analysis of clinical evidence 2020, Vol. 20 (28-31).
Vuylsteke V, Chastain L M, Maggu G A, Brown C; A Potential New Multi-Target Drug for Type 2 Diabetes journal of drug RD 2015, Vol (15) (227–232).
Doupis J, Baris N, Avramidis K; A New Promising and Effective Weapon in the Treatment of Type 2 Diabetes Journal of Internal Medicine and Diabetes 2021, vol. 17(2) (88–91).
Fouqueray P, Chevalier C, Bolze S; Pharmacokinetics of Imeglimin in Caucasian and Japanese healthy subjects journal of clinical drug investigation ,2022, vol. 42, (721–732).
Bozec S H, Vial G, Kergoat M, Fouqueray P, Bolze S, Borel AL, Fontaine E; A novel therapeutic agent for type 2 diabetes Journal of wiley online library 2020, vol. 10.1111 , (664- 673).
Vial G, Lamarche F, Rousselle C C, Bozec S H, Borel A L, Fontaine E; The mechanism by which imeglimin inhibits gluconeogenesis in rat liver cells Journal of wileyonline library 2020, Vol. 10(1002), (1-10).
Lachaux M, Soulie M, Hamzaoui M, Bailly A, Nicol L, Jouet I R, Renet S, Vendeville C, Dagorn P G, Bozec S H, Monteil C, Richard V, Mulder P; Short-and long-term administration of imeglimin counters cardiorenal dysfunction in a rat model of metabolic syndrome Journal of wiley online library, 2020, vol. 10.1002.
Theurey p, Vial G, Fontaine E, Monternier P A, Fouqueray P, Bolze S, Moller D E, Bozec S P, Reduced lactic acidosis risk with Imeglimin: Comparison with Metformin Journal of Wiley Periodicals LLC on behalf of The Physiological Society and the American Physiological Society 2021, vol. 10.14814
Sanada J, Obata A, Fushimi Y, Kimura T, Shimoda M, Ikeda T, Nogami Y, Obata O, Yamasaki Y, Nakanishi S, Mune T, Kaku K, Kaneto H Imeglimin exerts favorable effects on pancreatic β cells by improving morphology in mitochondria and increasing the number of insulin granules Journal of Diabetes, Endocrinology and Metabolism (2022) vol. 12:13220.
Konkwo C, Perry R J; Imeglimin current development and future potential in Type 2 Diabetes, Journal of HHS Public Access 2021 vol. 81(2), (185–190).
Singh A K, Singh A, Singh R, Misra A, Efficacy and safety of imeglimin in type 2 diabetes: A systematic review and meta-analysis of randomized placebo-controlled trials, Journal of Diabetes & Metabolic Syndrome 2023.
Detaille D, Vial G, Borel A L, Cottet-Rouselle C, Bozec S H, Bolze S, Fouqueray P; Fontaine E, Imeglimin prevents human endothelial cell death by inhibiting mitochondrial permeability transition without inhibiting mitochondrial respiration Journal of Cell Death Discovery (2016) vol. 2.
Reilhac C, Dubourg J, Thang C, Grouin J M, Fouqueray P, Watada H; Efficacy and safety of imeglimin add-on to insulin monotherapy in Japanese patients with type 2 diabetes. A randomized, double-blind, placebo-controlled phase 3 trial with a 36-week open-label extension period, Journal of Wiley Periodicals LLC on behalf of The Physiological Society and the American Physiological Society 2022, VOL. 24, (838–848).
Fauzi M, Murakami T, Fujimoto H, Botagarova A, Sakaki K, Kiyobayashi S, Ogura M, Inagaki N; Preservation effect of imeglimin on pancreatic b-cell mass. Noninvasive evaluation using In-exendin-4 SPECT/CT imaging and the perspective of mitochondrial involvements Journal Frontiers in Endocrinology, 2022, Vol. 13:1010825.
Bando H, Okada M, Iwatsuki N, Sakamoto K, Ogawa T, Improved HbA1c value by combined treatment of Dulaglutide and Imeglimin for patient with type 2 diabetes mellitus (T2DM) International Journal of Endocrinology and Diabetes 2022, vol. 5.1.
Oda T, Satoh M, Nagasawa K, Sasaki A, Hasegawa Y, Takebe N, Ishigaki Y; The Effects of Imeglimin on the Daily Glycemic Profile Evaluated by Intermittently Scanned Continuous Glucose Monitoring: Retrospective, Single-Center, Observational Study Journal of Division of Diabetes, Metabolism and Endocrinology, Department of Internal Medicine (2022) vol. 13, (1635–1643).
Raczynśka E D, Gal J F, Maria P C, Fontaine V F, Biguanide Antidiabetic Drugs. Imeglimin Exhibits Higher Proton Basicity but Smaller Lithium-Cation Basicity than Metformin in Vacuo Journal of ACS Omega 2018, vol. 3, (17842−17852).
Nomoto H, Takahashi A, Nakamura A, Kurihara H, Takeuchi J, Nagai S, Taneda S, Miya A, Kameda H, Yong Cho K, Miyoshi H, Atsumi T; Add-on imeglimin versus metformin dose escalation regarding glycemic control in patients with type 2 diabetes treated with a dipeptidyl peptidase-4 inhibitor plus low-dose metformin: study protocol for a multicenter, prospective, randomized, open-label, parallel-group comparison study (MEGMI study) BMJ Open Diab Research and Care 2022; vol.10.
Hagi K, Kochi K, Watada H, Kaku K, Ueki K, Effect of patient characteristics on the efficacy and safety of imeglimin monotherapy in Japanese patients with type 2 diabetes mellitus: A post-hoc analysis of two randomized, placebo-controlled trials Journal of Diabetes Investigation 2023,
Uchida T, Ueno H, Konagata A, Taniguchi N, Kogo F, Nagatomo Y, Shimizu K, Yamaguchi H, Shimoda K; Improving the effects of imeglimin on endothelial function: A prospective, single-center, observational study, Journal of Diabetes Ther (2023) vol. 14: (569–579).
Yamagishi H, Hoshino S, Hirano A, Oshima A, Imai T; Potential Ketoacidosis Linked to Imeglimin and Metformin Co-administration in a Patient With Type 2 Diabetes, Journal of cures (2023) vol. 15(6): (40702).
Dubourg J, Dauchy S P, Felices M, Bolze S, Voiriot P, Fouqueray P; Absence of QTc prolongation in a thorough QT study with imeglimin, a first in class oral agent for type 2 diabetes mellitus, European Journal of Clinical Pharmacology (2020) Vol. 76, (1393–1400).
Okada M, Bando H, Iwatsuki N, Sakamoto K, Ogawa T; elderly female of type 2 diabetes (T2D) and dementia with clinical improvement by Imeglimin (Twymeeg), Asp Biomed Clin Case Report, 2023 Feb 04;6(1), (17-22).
Jin Endo H K, Hashimoto S, Mizuno H, Moriyama H, Shirakawa K, Goto S, Katsumata Y, Fukuda K, Sano M, Imeglimin prevents heart failure with preserved ejection fraction by recovering the impaired unfolded protein response in mice subjected to cardiometabolic stress, Biochemical and Biophysical Research Communications (2021), Vol. 572, (185-190).
Nozu T, Saori Miyagishi S , Ishioh M , Takakusaki K, Okumura T, Imeglimin prevents visceral hypersensitivity and colonic hyperpermeability in irritable bowel syndrome rat model, Journal of Pharmacological Sciences (2023)Vol.153, (26-30).
Nowak M 1, Grzeszczak W; a new antidiabetic drug with potential for the treatment of patients with type 2 diabetes, Journal of Endokrynologia Polska 2022, Vol. 73
Sathawane Y J, Thakare S, Umekar A A, Lohiya R T, Development of Novel UvSpectrophotometric Method for Imeglimin Hydrochloride, International Journal of Pharmaceutical Research and Applications 2023,Vol. 8, (1637-1644).
Salvi A S, Khamkar M S, Hingane L D; Development and Validation of RP-HPLC method for estimation of anti-diabetic drug in bulk and tablet dosage form, Journal of emerging technologies and innovative research 2023, Vol. 10, (366-378).